Last edition
News about "Vigil Neuroscience"
Sanofi Acquires Vigil Neuroscience, Strengthens Neurodegenerative Disease Pipeline
Sanofi has completed its acquisition of Vigil Neuroscience, thereby strengthening its early-stage pipeline in neurology with the addition of VG-3927, an experimental drug candidate for Alzheimer's disease.
Vigil Neuroscience | 07/08/2025 | By Dineshwori | 103
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members